B
13.12
0.74 (5.98%)
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | BridgeBio Oncology Therapeutics | Menurun | - |
AISkor Stockmoo
0.4
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.38 |
|
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 27.00 (HC Wainwright & Co., 105.79%) | Beli |
| Median | 25.00 (90.55%) | |
| Rendah | 20.00 (Morgan Stanley, 52.44%) | Beli |
| Purata | 23.80 (81.40%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 11.79 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 05 Dec 2025 | 20.00 (52.44%) | Beli | 13.69 |
| Wedbush | 25 Nov 2025 | 25.00 (90.55%) | Beli | 12.36 |
| Oppenheimer | 13 Nov 2025 | 22.00 (67.68%) | Beli | 12.38 |
| Leerink Partners | 17 Sep 2025 | 25.00 (90.55%) | Beli | 10.79 |
| HC Wainwright & Co. | 15 Sep 2025 | 27.00 (105.79%) | Beli | 9.73 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |